Abstract
Purpose
To assess the effect of the intense pulse light (IPL) therapy for the treatment of meibomian gland dysfunction (MGD) and dry eye parameters.
Methods
Patients who underwent an IPL therapy for the treatment of MGD were included in this retrospective study. Ocular Surface Disease Index (OSDI) scores, the frequency of daily lubricant use, non-invasive tear break-up time (NIBUT), meibomian glad dropout scores, corneal staining scores, and Schirmer test results were collected from patient charts that recorded at baseline and follow-up visits at 1 month, 3 months, and 12 months. For the analysis, patients were grouped based on the severity of their baseline meibomian gland dropout score as mild, moderate, and severe atrophy.
Results
Forty-three patients (mild atrophy = 22, moderate atrophy = 17, and severe atrophy = 4) were included for analysis. Except for the Schirmer test, all dry eye parameters significantly improved in patients with mild and moderate atrophy following the treatment and this effect lasted until the 12-month follow-up visit (p < 0.001). No significant improvement in any parameter was observed in patients with severe atrophy at any time point (p > 0.05). In the mild and moderate atrophy groups, OSDI scores, as well as NIBUT, started improving at 1 month (p < 0.01), while corneal staining and meibomian gland dropout scores showed earliest improvements at 3 months (p < 0.01). No adverse events were observed, except for temporary redness in 4 patients.
Conclusion
The IPL treatment seems an effective and safe treatment for patients with MGD. This study shows that the IPL resulting in an earlier improvement in symptoms and signs with long-lasting beneficial effect on the meibomian glands.
Similar content being viewed by others
References
Ding J, Sullivan DA (2012) Aging and dry eye disease. Exp Gerontol 47:483–490
Nelson JD, Shimazaki J, Benitez-del-Castillo JM, Craig JP, McCulley JP, Den S, Foulks GN (2011) The international workshop on meibomian gland dysfunction: report of the definition and classification subcommittee. Invest Ophthalmol Vis Sci 52:1930–1937
Lane SS, DuBiner HB, Epstein RJ, Ernest PH, Greiner JV, Hardten DR et al (2012) A new system, the LipiFlow, for the treatment of meibomian gland dysfunction. Cornea 31(4):396–404
Toyos R, McGill W, Briscoe D (2015) Intense pulsed light treatment for dry eye disease due to meibomian gland dysfunction; a 3-year retrospective study. Photomed Laser Surg 33:41–46
Gupta PK, Vora GK, Matossian C, Kim M, Stinnett S (2016) Outcomes of intense pulsed light therapy for treatment of evaporative dry eye disease. Can J Ophthalmol 51:249–253
Vegunta S, Patel D, Shen JF (2016) Combination therapy of intense pulsed light therapy and meibomian gland expression (IPL/MGX) can improve dry eye symptoms and meibomian gland function in patients with refractory dry eye: a retrospective analysis. Cornea 35:318–322
Craig JP, Chen YH, Turnbull PR (2015) Prospective trial of intense pulsed light for the treatment of meibomian gland dysfunction. Invest Ophthalmol Vis Sci 56:1965–1970
Yin Y, Liu N, Gong L, Song N (2018) Changes in the meibomian gland after exposure to intense pulsed light in meibomian gland dysfunction (MGD) patients. Curr Eye Res 43:308–313
Albietz JM, Schmid KL (2018) Intense pulsed light treatment and meibomian gland expression for moderate to advanced meibomian gland dysfunction. Clin Exp Optom 101:23–33
Vora GK, Gupta PK (2015) Intense pulsed light therapy for the treatment of evaporative dry eye disease. Curr Opin Ophthalmol 26:314–318
Walt J (2004) Ocular Surface Disease Index (OSDI) administration and scoring manual. Allergan Inc., Irvine
Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22:640–650
Gupta PK, Stevens MN, Kashyap N, Priestley Y (2018) Prevalence of meibomian gland atrophy in a pediatric population. Cornea 37:426–430
Kang YS, Lee HS, Li Y, Choi W, Yoon KC (2018) Manifestation of meibomian gland dysfunction in patients with Sjögren’s syndrome, non-Sjögren’s dry eye, and non-dry eye controls. Int Ophthalmol 38:1161–1167
Fitzpatrick TB (1988) The validity and practicality of sun-reactive skin types I through VI. Arch Dermatol 124:869–871
Dell SJ, Gaster RN, Barbarino SC, Cunningham DN (2017) Prospective evaluation of intense pulsed light and meibomian gland expression efficacy on relieving signs and symptoms of dry eye disease due to meibomian gland dysfunction. Clin Ophthalmol 11:817–827
Seo KY, Kang SM, Ha DY, Chin HS, Jung JW (2018) Long-term effects of intense pulsed light treatment on the ocular surface in patients with rosacea-associated meibomian gland dysfunction. Contact Lens Anterior Eye 41:430–435
Arita R, Mizoguchi T, Fukuoka S, Morishige N (2018) Multicenter study of intense pulsed light therapy for patients with refractory meibomian gland dysfunction. Cornea 37:1566–1571
Dell SJ (2017) Intense pulsed light for evaporative dry eye disease. Clin Ophthalmol 11:1167–1173
Karaca EE, Evren Kemer O, Ozek D (2018) Intense regulated pulse light for the meibomian gland dysfunction. Eur J Ophthalmol, p 1120672118817687. 4 Dec 2018 [Online ahead of print]
Messmer EM (2015) The pathophysiology, diagnosis, and treatment of dry eye disease. Dtsch Arztebl Int 112:71–81
Funding
Intense pulse light dry eye treatment platform was provided by Espansione group (Bologna, Italy) for the duration of the study. The funding organization had no role in the design or conduct of this research.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
No conflicting relationship exists for any author.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Yurttaser Ocak, S., Karakus, S., Ocak, O.B. et al. Intense pulse light therapy treatment for refractory dry eye disease due to meibomian gland dysfunction. Int Ophthalmol 40, 1135–1141 (2020). https://doi.org/10.1007/s10792-019-01278-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10792-019-01278-3